Glenmark Pharma reports consolidated revenue growth of 6.3% and adjusted EBITDA growth of 8.3% YoY for Q2 FY 2023-24
Highlights for Q2 FY 2023-24 Europe Business grew by 58.4% to Rs. 5,997 Mn.RoW Business grew by 19% to Rs. 7,324 Mn.India Business grew by 2.8% to Rs. 11,217 Mn.North America Business declined by 1.9% to Rs. ...
Read more